| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total other income | 256 | 1,391 | 298 | 576 |
| Loss before income tax expense | -5,981 | -7,435 | -8,543 | -11,866 |
| Income tax expense | 3 | 2 | 4 | 7 |
| Net loss | -5,984 | -7,437 | -8,547 | -11,873 |
| Unrealized holding income (loss) on short-term investments, net of tax | 0 | 0 | - | 24 |
| Comprehensive loss | -5,984 | -7,437 | -8,547 | -11,849 |
| Earnings per share, basic, total | -3.38 | -5.51 | -0.13 | -0.18 |
| Earnings per share, diluted, total | -3.38 | -5.51 | -0.13 | -0.18 |
| Weighted average number of shares outstanding, basic, total | 1,767,814 | 1,348,630 | 65,757,860 | 65,456,735 |
| Weighted average number of shares outstanding, diluted, total | 1,767,814 | 1,348,630 | 65,757,860 | 65,456,735 |
Lyra Therapeutics, Inc. (LYRA)
Lyra Therapeutics, Inc. (LYRA)